NCT05833893View on ClinicalTrials.gov

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
nk/T-cell LymphomaNewly DiagnosedAdvanced Lymphoma
Interventions
DRUG

XPO1 inhibitor

COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)

Trial Locations (1)

100853

RECRUITING

ChinaPLAGH, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER